BioSpace News Archive

Campaign Designed to Drive Discussion About Treatment Innovations; Activities to Include National Media Tour and Town Hall Meetings Throughout the U.S.

New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will release its first quarter 2019 earnings results on Wednesday, May 1, 2019 after the close of the market.

Novartis announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD.

BioPharmX Corporation announced that its Board of Directors has approved a reverse stock split of its common stock at a ratio of 1-for-25.

Adare Pharmaceuticals, Inc. announced that it has entered into an agreement with Egalet Corporation, to acquire global rights of the “ParvuletTM” technology platform and its associated Intellectual Property.

A Kentucky woman filed the first lawsuit in the nation in the Salmonella outbreak linked to pre-cut melons produced by Caito Foods.

Hagens Berman Sobol Shapiro LLP alerts investors in Zogenix, Inc. to the firm’s investigation of possible Federal securities law violations.

Rocket Pharmaceuticals, Inc. announces the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $17.50 per share.

CB-012 demonstrates potent antiviral activity against influenza A and B viruses